Viral vector-based gene transfer for treatment of chronic pain

International Anesthesiology Clinics

Volumn 45, Issue 2, 2007, Pages 59-71

  Hao, Shuanglin ^a,b   Mata, Marina ^a   Fink, David J ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BETA ENDORPHIN; BRAIN DERIVED NEUROTROPHIC FACTOR; ENKEPHALIN; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; HERPESVIRUS VECTOR; INTERLEUKIN 10; INTERLEUKIN 4; MORPHINE; MU OPIATE RECEPTOR; PARVOVIRUS VECTOR; PROENKEPHALIN;

ADENO ASSOCIATED VIRUS; ADENOVIRUS; ALLODYNIA; CANCER PAIN; CENTRAL NERVOUS SYSTEM; CHRONIC PAIN; CLINICAL TRIAL; DRUG DOSE REDUCTION; GENE TRANSFER; HERPES SIMPLEX VIRUS; HUMAN; HYPERALGESIA; NEUROLOGIC DISEASE; NEUROPATHIC PAIN; NONHUMAN; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; REVIEW; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ADENOVIRIDAE; ANIMALS; CHRONIC DISEASE; GENE THERAPY; GENETIC VECTORS; HUMANS; PAIN; SIMPLEXVIRUS;

EID: 34247209700     PISSN: 00205907     EISSN: None     Source Type: Journal    
DOI: 10.1097/AIA.0b013e318034199c     Document Type: Review

References (71)

1. Collins SL, Moore RA, McQuay HJ, et al. Antidepressants and anticonvulsants for diabetic neuropathy and postherpetic neuralgia: a quantitative systematic review. J Pain Symptom Manage. 2000;20:449-458.
2. Lai J, Ossipov MH, Vanderah TW, et al. Neuropathic pain: the paradox of dynorphin. Mol Interv. 2001;1:160-167.
3. Wu CL, Garry MG, Zollo RA, et al. Gene therapy for the management of pain: Part I: methods and strategies. Anesthesiology. 2001;94:1119-1132.
4. Watkins LR, Milligan ED, Maier SF. Glial activation: a driving force for pathological pain. Trends Neurosci. 2001;24:450-455.
5. Friedmann T, Roblin R. Gene therapy for human genetic disease?. Science. 1972; 175:949-955.
6. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science. 2000;288:669-672.
7. Glorioso JC, Mata M, Fink DJ. Therapeutic gene transfer to the nervous system using viral vectors. J Neurovirol. 2003;9:165-172.
8. Hermens WT, Verhaagen J. Viral vectors, tools for gene transfer in the nervous system. Prog Neurobiol. 1998;55:399-432.
9. Nabel GJ. Development of optimized vectors for gene therapy. Proc Natl Acad Sci U S A. 1999;96:324-326.
10. Fraefel C, Breakefield XO, Jacoby DR. HSV-1 amplicon. In: Chiocca EA, Breakefield XO, eds. Gene Therapy for Neurological Disorders and Brain Tumors. Totowa, NJ: Humana Press; 1998:63-82.
11. Smith JG, Eck SL. Immune response to viral vectors. In: Chiocca EA, Breakefield XO, eds. Gene Therapy for Neurological Disorders and Brain Tumors. Totowa, NJ: Humana Press; 1998:147-157.
12. Walther W, Stein U. Viral vectors for gene transfer: a review of their use in the treatment of human diseases. Drugs. 2000;60:249-271.
13. Kozarsky KF, Wilson JM. Gene therapy: adenovirus vectors. Curr Opin Genet Dev. 1993;3:499-503.
14. Chanock RM, Ludwig W, Heubner RJ, et al. Immunization by selective infection with type 4 adenovirus grown in human diploid tissue cultures. I. Safety and lack of oncogenicity and tests for potency in volunteers. JAMA. 1966;195:445-452.
15. Blomer U, Naldini L, Kafri T, et al. Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector. J Virol. 1997;71:6641-6649.
16. Finegold AA, Mannes AJ, Iadarola MJ. A paracrine paradigm for in vivo gene therapy in the central nervous system: treatment of chronic pain. Hum Gene Ther. 1999; 10:1251-1257.
17. Moore KW, de Waal Malefyt R, Coffman RL, et al. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol. 2001;19:683-765.
18. Milligan ED, Langer SJ, Sloane EM, et al. Controlling pathological pain by adenovirally driven spinal production of the anti-inflammatory cytokine, interleukin-10. Eur J Neurosci. 2005;21:2136-2148.
19. Hanisch UK, Quirion R. Interleukin-2 as a neuroregulatory cytokine. Brain Res Rev. 1995;21:246-284.
20. Jiang CL, Lu CL. Interleukin-2 and its effects in the central nervous system. Biol Signals Recept. 1998;7:148-156.
21. Song P, Zhao ZQ, Liu XY. Expression of IL-2 receptor in dorsal root ganglion neurons and peripheral antinociception. Neuroreport. 2000;11:1433-1436.
22. Wang Y, Pei G, Cai YC, et al. Human interleukin-2 could bind to opioid receptor and induce corresponding signal transduction. Neuroreport. 1996;8:11-14.
23. Zhao ZQ, Yang HQ, Liu XY. Inhibitory action of immunoregulator interleukin-2 on pain-sensitive spinal neurons in the cat. Chin J Neurosci. 1994;1:37-42.
24. Yao MZ, Gu JF, Wang JH, et al. Adenovirus-mediated interleukin-2 gene therapy of nociception. Gene Ther. 2003;10:1392-1399.
25. Srivastava A, Lusby EW, Berns KI. Nucleotide sequence and organization of the adeno-associated virus 2 genome. J Virol. 1983;45:555-564.
26. Xiao W, Chirmule N, Berta SC, et al. Gene therapy vectors based on adeno-associated virus type 1. J Virol. 1999;73:3994-4003.
27. Summerford C, Samulski RJ. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol. 1998;72:1438-1445.
28. Kaplitt MG, Leone P, Samulski RJ, et al. Long term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat Genet. 1994;8:148-154.
29. Woolf CJ, Salter MW. Neuronal plasticity: increasing the gain in pain. Science. 2000;288:1765-1769.
30. Woolf CJ, Costigan M. Transcriptional and posttranslational plasticity and the generation of inflammatory pain. Proc Natl Acad Sci U S A. 1999;96:7723-7730.
31. South SM, Kohno T, Kaspar BK, et al. A conditional deletion of the NR1 subunit of the NMDA receptor in adult spinal cord dorsal horn reduces NMDA currents and injury-induced pain. J Neurosci. 2003;23:5031-5040.
32. Xu Y, Gu Y, Wu P, et al. Efficiencies of transgene expression in nociceptive neurons through different routes of delivery of adeno-associated viral vectors. Hum Gene Ther. 2003;14:897-906.
33. Xu Y, Gu Y, Xu GY, et al. Adeno-associated viral transfer of opioid receptor gene to primary sensory neurons: a strategy to increase opioid antinociception. Proc Natl Acad Sci U S A. 2003;100:6204-6209.
34. Ohsawa F, Widmer HR, Knusel B, et al. Response of embryonic rat hippocampal neurons in culture to neurotropin-3, brain-derived neurotrophic factor and basic fibroblast factor. Neurosci. 1993;57:67-77.
35. Hyman C, Juhasz M, Jackson C, et al. Overlapping and distinct actions of the neurotrophins BDNF,NT-3 and NT-4/5 on cultured dopaminergic and GABAergic neurons of the ventral mesencephalon. J Neurosci. 1994;14:335-347.
36. Martin-Iverson MT, Todd KG, Altar CA. Brain-derived neurotrophic factor and neurotrophin-3 activate striatal dopamine and serotonin metabolism and related behaviors: interactions with amphetamine. J Neurosci. 1994;14:1262-1270.
37. Eaton MJ, Blits B, Ruitenberg MJ, et al. Amelioration of chronic neuropathic pain after partial nerve injury by adeno-associated viral (AAV) vector-mediated overexpression of BDNF in the rat spinal cord. Gene Ther. 2002;9:1387-1395.
38. Milligan ED, Sloane EM, Langer SJ, et al. Controlling neuropathic pain by adenoassociated virus driven production of the anti-inflammatory cytokine, interleukin-10. Mol Pain. 2005;1:9.
39. Sala C, Piech V, Wilson NR, et al. Regulation of dendritic spine morphology and synaptic function by Shank and Homer. Neuron. 2001;31:115-130.
40. Tu JC, Xiao B, Yuan JP, et al. Homer binds a novel proline-rich motif and links group 1 metabotropic glutamate receptors with IP3 receptors. Neuron. 1998;21:717-726.
41. Sala C, Futai K, Yamamoto K, et al. Inhibition of dendritic spine morphogenesis and synaptic transmission by activity-inducible protein Homer1a. J Neurosci. 2003; 23:6327-6337.
42. Tappe A, Klugmann M, Luo C, et al. Synaptic scaffolding protein Homer1a protects against chronic inflammatory pain. Nat Med. 2006;12:677-681.
43. Newcomb WW, Homa FL, Thomsen DR, et al. Assembly of the herpes simplex virus procapsid from purified components and identification of small complexes containing the major capsid and scaffolding proteins. J Virol. 1999;73:4239-4250.
44. Campbell MEM, Palfeyman JW, Preston CM. Identification of herpes simplex virus DNA sequences which encode a trans-acting polypeptide responsible for stimulation of immediate early transcription. J Mol Biol. 1984;180:1-19.
45. Preston C, Frame M, Campbell M. A complex formed between cell components and an HSV structural polypeptide binds to a viral immediate early gene regulatory DNA sequence. Cell. 1988;52:425-434.
46. Honess RW, Roizman B. Regulation of herpesvirus macromolecular synthesis. I. Cascade regulation of the synthesis of three groups of viral proteins. J Virol. 1974;14:8-19.
47. Sodeik B, Ebersold MW, Helenius A. Microtubule-mediated transport of incoming herpes simplex virus 1 capsids to the nucleus. J. Cell Biol. 1997;136:1007-1021.
48. Glorioso JC, Fink DJ. Herpes vector-mediated gene transfer in treatment of diseases of the nervous system. Annu Rev Microbiol. 2004;58:253-271.
49. Yaksh TL, Hua XY, Kalcheva I, et al. The spinal biology in humans and animals of pain states generated by persistent small afferent input. Proc Natl Acad Sci U S A. 1999;96:7680-7686.
50. Wilson SP, Yeomans DC, Bender MA, et al. Antihyperalgesic effects of infection with a preproenkephalin-encoding herpes virus. Proc Natl Acad Sci U S A. 1999; 96:3211-3216.
51. Antunes Bras JM, Epstein AL, Bourgoin S, et al. Herpes simplex virus 1-mediated transfer of preproenkephalin A in rat dorsal root ganglia. J Neurochem. 1998;70: 1299-1303.
52. Braz J, Beaufour C, Coutaux A, et al. Therapeutic efficacy in experimental polyarthritis of viral-driven enkephalin overproduction in sensory neurons. J Neurosci. 2001;21:7881-7888.
53. Goss JR, Mata M, Goins WF, et al. Antinociceptive effect of a genomic herpes simplex virus-based vector expressing human proenkephalin in rat dorsal root ganglion. Gene Ther. 2001;8:551-556.
54. Yeomans DC, Lu Y, Laurito CE, et al. Recombinant herpes vector-mediated analgesia in a primate model of hyperalgesia. Mol Ther. 2006;13:589-597.
55. Kang W, Wilson MA, Bender MA, et al. Herpes virus-mediated preproenkephalin gene transfer to the amygdala is antinociceptive. Brain Res. 1998;792:133-135.
56. Kim SH, Chung JM. An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain. 1992;50:355-363.
57. Hao S, Mata M, Goins W, et al. Transgene-mediated enkephalin release enhances the effect of morphine and evades tolerance to produce a sustained antiallodynic effect in neuropathic pain. Pain. 2003;102:135-142.
58. Goss JR, Harley CF, Mata M, et al. Herpes vector-mediated expression of proenkephalin reduces bone cancer pain. Ann Neurol. 2002;52:662-665.
59. Vos BP, Strassman AM, Maciewicz RJ. Behavioral evidence of trigeminal neuropathic pain following chronic constriction injury to the rat's infraorbital nerve. J Neurosci. 1994;14:2708-2723.
60. Meunier A, Latremoliere A, Mauborgne A, et al. Attenuation of pain-related behavior in a rat model of trigeminal neuropathic pain by viral-driven enkephalin overproduction in trigeminal ganglion neurons. Mol Ther. 2005;11:608-616.
61. Boucher TJ, Okuse K, Bennett DL, et al. Potent analgesic effects of GDNF in neuropathic pain states. Science. 2000;290:124-127.
62. Hao S, Mata M, Wolfe D, et al. HSV-mediated gene transfer of the glial cell-derived neurotrophic factor provides an antiallodynic effect on neuropathic pain. Mol Ther. 2003;8:367-375.
63. Moore KA, Kohno T, Karchewski LA, et al. Partial peripheral nerve injury promotes a selective loss of GABAergic inhibition in the superficial dorsal horn of the spinal cord. J Neurosci. 2002;22:6724-6731.
64. Hao S, Mata M, Wolfe D, et al. Gene transfer of glutamic acid decarboxylase reduces neuropathic pain. Ann Neurol. 2005;57:914-918.
65. Liu J, Wolfe D, Hao S, et al. Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain. Mol Ther. 2004;10:57-66.
66. Verri WA Jr. Hypernociceptive role of cytokines and chemokines: targets for analgesic drug development? Pharmacol Ther. 2006;112:116-138.
67. Vale ML, Marques JB, Moreira CA. Antinociceptive effects of interleukin-4, -10, and -13 on the writhing response in mice and zymosan-induced knee joint incapacitation in rats. J Pharmacol Exp Ther. 2003;304:102-108.
68. Hao S, Mata M, Glorioso JC, et al. HSV-mediated expression of interleukin-4 in dorsal root ganglion neurons reduces neuropathic pain. Mol Pain. 2006;2:6.
69. Homma Y, Brull SJ, Zhang JM. A comparison of chronic pain behavior following local application of tumor necrosis factor alpha to the normal and mechanically compressed lumbar ganglia in the rat. Pain. 2002;95:239-246.
70. Peng XM, Zhou ZG, Glorioso JC, et al. Tumor necrosis factor-alpha contributes to below-level neuropathic pain after spinal cord injury. Ann Neurol. 2006;59:843-851.
71. Mata M, Glorioso JC, Fink DJ. Targeted gene delivery to the nervous system using herpes simplex virus vectors. Physiol Behav. 2002;77:483-488.